Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by THOMAS WHEELER and TIMOTHY THOMPSON.
THOMAS WHEELER
Connection Strength
1.641
TIMOTHY THOMPSON
  1. Apoptotic index as a biomarker in prostatic intraepithelial neoplasia (PIN) and prostate cancer. J Cell Biochem Suppl. 1994; 19:202-7.
    View in: PubMed
    Score: 0.117
  2. Correlative evidence that prostate cancer cell-derived caveolin-1 mediates angiogenesis. Hum Pathol. 2007 Nov; 38(11):1688-95.
    View in: PubMed
    Score: 0.075
  3. Stromal antiapoptotic paracrine loop in perineural invasion of prostatic carcinoma. Cancer Res. 2006 May 15; 66(10):5159-64.
    View in: PubMed
    Score: 0.069
  4. Bystin in perineural invasion of prostate cancer. Prostate. 2006 Feb 15; 66(3):266-72.
    View in: PubMed
    Score: 0.068
  5. Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. Cancer. 2005 Mar 15; 103(6):1186-94.
    View in: PubMed
    Score: 0.063
  6. The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis. 2005; 8(2):108-18.
    View in: PubMed
    Score: 0.063
  7. Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients. Int J Radiat Oncol Biol Phys. 2004 Jun 01; 59(2):562-71.
    View in: PubMed
    Score: 0.060
  8. Reduced infiltration of class A scavenger receptor positive antigen-presenting cells is associated with prostate cancer progression. Cancer Res. 2004 Mar 15; 64(6):2076-82.
    View in: PubMed
    Score: 0.059
  9. Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 1):3653-9.
    View in: PubMed
    Score: 0.057
  10. The role of caveolin-1 in androgen insensitive prostate cancer. J Urol. 2002 Oct; 168(4 Pt 1):1589-96.
    View in: PubMed
    Score: 0.053
  11. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther. 2001 Nov 01; 12(16):1955-67.
    View in: PubMed
    Score: 0.050
  12. In situ gene therapy for prostate cancer: immunomodulatory approaches. Expert Opin Biol Ther. 2001 May; 1(3):481-95.
    View in: PubMed
    Score: 0.048
  13. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res. 2000 Oct 15; 60(20):5857-61.
    View in: PubMed
    Score: 0.047
  14. Elevated caveolin-1 levels in African-American versus white-American prostate cancer. Clin Cancer Res. 2000 Sep; 6(9):3430-3.
    View in: PubMed
    Score: 0.046
  15. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res. 1999 Nov 15; 59(22):5719-23.
    View in: PubMed
    Score: 0.044
  16. Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis. Mod Pathol. 1999 Aug; 12(8):751-5.
    View in: PubMed
    Score: 0.043
  17. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res. 1998 Aug; 4(8):1873-80.
    View in: PubMed
    Score: 0.040
  18. Reduced lysyl oxidase messenger RNA levels in experimental and human prostate cancer. Cancer Res. 1998 Mar 15; 58(6):1285-90.
    View in: PubMed
    Score: 0.039
  19. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer. 1998 Jan 01; 82(1):168-75.
    View in: PubMed
    Score: 0.038
  20. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin Cancer Res. 1997 Aug; 3(8):1389-97.
    View in: PubMed
    Score: 0.037
  21. Perineural invasion of prostate carcinoma cells is associated with reduced apoptotic index. Cancer. 1996 Sep 15; 78(6):1267-71.
    View in: PubMed
    Score: 0.035
  22. Reduced levels of transforming growth factor beta receptor type II in human prostate cancer: an immunohistochemical study. Clin Cancer Res. 1996 Apr; 2(4):635-40.
    View in: PubMed
    Score: 0.034
  23. Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression. Clin Cancer Res. 1996 Feb; 2(2):399-401.
    View in: PubMed
    Score: 0.034
  24. Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res. 1995 Oct; 1(10):1111-8.
    View in: PubMed
    Score: 0.033
  25. The frequency of apoptosis correlates with the prognosis of Gleason Grade 3 adenocarcinoma of the prostate. Cancer. 1995 Jan 15; 75(2):522-9.
    View in: PubMed
    Score: 0.031
  26. Frequency of apoptotic bodies positively correlates with Gleason grade in prostate cancer. Hum Pathol. 1994 Aug; 25(8):797-801.
    View in: PubMed
    Score: 0.030
  27. GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res. 2011 Nov 15; 17(22):7174-82.
    View in: PubMed
    Score: 0.025
  28. Cancer-related axonogenesis and neurogenesis in prostate cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7593-603.
    View in: PubMed
    Score: 0.020
  29. Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt. Clin Cancer Res. 2008 Nov 15; 14(22):7511-8.
    View in: PubMed
    Score: 0.020
  30. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res. 2007 Dec 01; 13(23):6947-58.
    View in: PubMed
    Score: 0.019
  31. Forkhead protein FKHR and its phosphorylated form p-FKHR in human prostate cancer. Hum Pathol. 2007 Oct; 38(10):1501-7.
    View in: PubMed
    Score: 0.019
  32. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res. 2006 Aug 15; 12(16):4872-5.
    View in: PubMed
    Score: 0.017
  33. Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Mol Ther. 2006 Apr; 13(4):716-28.
    View in: PubMed
    Score: 0.017
  34. Expanding the therapeutic index of radiation therapy by combining in situ gene therapy in the treatment of prostate cancer. Technol Cancer Res Treat. 2006 Feb; 5(1):23-36.
    View in: PubMed
    Score: 0.017
  35. Pim-2 upregulation: biological implications associated with disease progression and perinueral invasion in prostate cancer. Prostate. 2005 Nov 01; 65(3):276-86.
    View in: PubMed
    Score: 0.017
  36. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res. 2004 Oct 01; 10(19):6572-8.
    View in: PubMed
    Score: 0.015
  37. Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res. 2004 Sep 01; 64(17):6082-90.
    View in: PubMed
    Score: 0.015
  38. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am J Surg Pathol. 2004 Jul; 28(7):928-34.
    View in: PubMed
    Score: 0.015
  39. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1520-9.
    View in: PubMed
    Score: 0.015
  40. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res. 2002 Nov; 8(11):3419-26.
    View in: PubMed
    Score: 0.013
  41. Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancer. Oncologist. 2002; 7(5):458-66.
    View in: PubMed
    Score: 0.013
  42. Cytopathic effect of in situ gene therapy in prostate cancer. Hum Pathol. 2000 Jul; 31(7):866-70.
    View in: PubMed
    Score: 0.011
  43. Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia. Oncogene. 2000 Apr 27; 19(18):2186-93.
    View in: PubMed
    Score: 0.011
  44. Differential expression of nuclear retinoid receptors in normal and malignant prostates. J Clin Oncol. 2000 Jan; 18(1):116-21.
    View in: PubMed
    Score: 0.011
  45. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther. 1999 May 01; 10(7):1239-49.
    View in: PubMed
    Score: 0.011
  46. Quantitative immunohistochemical analysis of insulin-like growth factor binding protein-3 in human prostatic adenocarcinoma: a prognostic study. J Urol. 1998 Jun; 159(6):2220-5.
    View in: PubMed
    Score: 0.010
  47. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol. 1994 Nov; 152(5 Pt 2):1843-9.
    View in: PubMed
    Score: 0.008
  48. Some small prostate cancers are nondiploid by nuclear image analysis: correlation of deoxyribonucleic acid ploidy status and pathological features. J Urol. 1994 May; 151(5):1301-7.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.